Therapeutic focus areas
We’re constantly finding new ways to address patients’ most serious health issues. We concentrate our efforts on a core set of therapeutic areas—ones where we’ve proven our expertise, and where we feel we can have an even greater impact on disease and how it is managed.
Immunology
Focusing on ground-breaking medicines to address chronic progressive diseases, including in rheumatology, dermatology, and gastroenterology.
Oncology
Investing in new pathways, technologies and approaches to tackle the most widespread and debilitating cancers.
Neuroscience
Discovering compounds that have the potential to treat chronic disabling neurological conditions and impairments, including MS, Parkinson’s Disease and Alzheimer’s.
Virology
Partnering with patient advocates and leading stakeholders to help address unmet needs across the world for people living with HIV-1 and hepatitis C.
Aesthetics
We are driven to help consumers make informed decisions about their aesthetic needs.
Other specialty areas
We continue to focus on research and development for other disease areas of significant need, always with an improved quality of life for patients in mind.
We are currently investigating a treatment for symptoms related to endometriosis and uterine fibroids—diseases that affect millions of women throughout the world. Both conditions are highly prevalent and are associated with a number of chronic complications.
Cystic fibrosis (CF) is a rare, life-threatening, genetic disease that affects between 70,000 and 100,000 patients worldwide. In the US and UK, average life expectancy is 35 to 40 years old. In countries such as El Salvador, India and Bulgaria, life expectancy drops to below 15. There currently is no cure for CF. We are currently evaluating investigational compounds in early clinical phases for a triple combination therapy.
Diabetic nephropathy, or diabetic kidney disease, is a common complication of diabetes and the leading cause of chronic kidney disease in the developing world. We are currently conducting a clinical study to assess the effects of an investigational drug on progression of kidney disease in patients with state 2 to 4 CKD and type 2 diabetes.
